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Background: There is relatively little methylation array data available specifically for oral squamous cell carcinoma (OSCC). This
study aims to compare the DNA methylome across a large cohort of tumour/normal pairs.
Methods: DNA was extracted from 44 OSCCs and paired normal mucosa. DNA methylation analysis employed the Illumina
GoldenGate high-throughput array comprising 1505 CpG loci selected from 807 epigenetically regulated genes. This data was
correlated with extracapsular spread (ECS), human papilloma virus (HPV) status, recurrence and 5-year survival.
Results: Differential methylation levels of a number of genes distinguished the tumour tissue sample from the matched normal.
Putative methylation signatures for ECS and recurrence were identified. The concept of concordant methylation or CpG island
methylator phenotype (CIMP) in OSCC is supported by our data, with an association between ‘CIMP-high’ and worse prognosis.
Epigenetic deregulation of NOTCH4 signalling in OSCC was also observed, as part of a possible methylation signature for
recurrence, with parallels to recently discovered NOTCH mutations in HNSCC. Differences in methylation in HPV-driven cases
were seen, but are less significant than that has been recently proposed in other series.
Conclusion: Although OSCC seems as much an ‘epigenetic’ as a genetic disease, the translational potential of cancer epigenetics
has yet to be fully exploited. This data points to the application of epigenetic biomarkers and targets available to further the
development of therapy in OSCC.
Head and neck squamous cell carcinoma (HNSCC) is the sixth
most common malignancy with a worldwide incidence of 615 000
cases per annum, of which around 300 000 are oral squamous cell
carcinomas (OSCC) (Kademani, 2007). The UK incidence of
OSCC has recently increased, reaching over 6000 cases per annum
(CR-UK press release, 2012). It is now apparent that cancer is as
much a disease of misdirected epigenetics as genetic mutations,
losses and amplifications, and recent published evidence suggests
that as many as 5% of known gene promoters (i.e. 1500–2000
genes) are abnormally methylated in a typical solid tumour
(Schuebel et al, 2007) compared with, typically, 11 gene mutations
(Sjoblom et al, 2006). Next generation sequencing in HNSCC has
shown that, although common in TP53 and NOTCH pathways,
somatic mutations in specific genes are relatively heterogeneous,
individually occurring in o10% of cases (Agrawal et al, 2011).
Detection of methylation at known target CpG sequences can be
made highly sensitive, opening up the possibility of the develop-
ment of minimally invasive biomarkers in body fluid surrogates
(Laird, 2003; Shaw et al, 2006a). However, genome-wide methyla-
tion platforms have lagged behind other genomic methods because
bisulphite conversion necessitates an inherent loss of sequence
complexity resulting in lack of hybridisation specificity. Conse-
quently, the literature has concentrated on a rather narrow cohort
(Ha and Califano, 2006; Shaw, 2006) of methylated gene
promoters, and the translational potential of the broader DNA
methylome in HNSCC remains relatively unexplored. The concept
of a CpG island methylator phenotype (CIMP) (Toyota et al,
1999), although well explored in several tumour types, has yet to be
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investigated in genome wide or array approach in OSCC (Shaw
et al, 2007).
More recently, high-throughput, genome-wide quantitative
methylation platforms have become available, allowing a more
comprehensive overview of DNA methylation (Bibikova et al,
2006; Bibikova and Fan, 2009). These arrays have been subject to
technical validation, showing good correlation of quantitative
methylation data with single gene assays (Bibikova et al, 2006).
Reassuringly, available data shows that copy number alterations
have little impact on methylation data in such arrays (Houseman
et al, 2009). Although some studies have concentrated on the
methylation signature in HSNCC cell lines, it is now appreciated
that the culture conditions introduce significant epigenetic
artefacts and clinically relevant data might only be available from
primary tumour tissue or xenografts (Hennessey et al, 2011). It is
known that the DNA methylome differs significantly across
different HNSCC subsites (Poage et al, 2011), and that there
may be differences between human papillomavirus (HPV)-related
and unrelated cases (Sartor et al, 2011). In an attempt to control for
these known sources of variation, it is reasonable to interrogate the
clinical correlates of DNA methylation in a single subsite of
HNSCC. Previous methylation array studies have made useful
contributions but have aggregated HNSCC sites in their analyses
(Poage et al, 2010, 2011). In the case of OSCC, subsequent analyses
will largely exclude the influence of HPV (Lopes et al, 2011), which
has been shown to be significant in only a minority of cases,
although this should be confirmed experimentally. Extracapsular
spread within cervical metastases (ECS) is the single most
predictive adverse feature for recurrence and survival in OSCC
(Shaw et al, 2010), being far more significant than metastasis per se.
Although the mechanism underlying ECS is poorly understood,
there is significant support for a contributory role of the stroma
(Marsh et al, 2011), perhaps through recruited cancer associated
fibroblasts (Quante et al, 2011). There is also evidence for
epigenetic co-ordination of these paracrine tumour/stromal
interactions (Jiang et al, 2008), thus it is logical to explore the
correlation between ECS and DNA methylation. In this study, we
interrogate methylation profiles of a series of OSCC, comparing
matched tumour and normal paired tissues. We correlate
significant tumour-specific changes with clinicopathological char-
acteristics, in particular, recurrence and survival, opening direc-
tions for future biomarker and mechanistic studies in OSCC.
MATERIALS AND METHODS
Clinical. Forty four OSCC patients were selected for inclusion in
this study, all of whom provided informed consent under a specific
institutional ethical approval (REC EC.47.01), between May 2006
and March 2007. Inclusion criteria included histologically
confirmed OSCC with a treatment decision for primary surgery.
At the time of surgery, 5 mm3 tumour samples were excised from
resected specimens within the tumour mass, but not involving the
margin. Normal samples of similar dimension were taken from the
resection margin, B10 mm from the macroscopic tumour edge
and subsequently confirmed as benign by routine histopathology.
Tumour and matched normal samples were snap-frozen and
stored at  80 1C until DNA preparation. Detailed histopatholo-
gical analysis was recorded for each surgical resection and the
clinical outcome for each patient was recorded at 5th year follow-
up. The Office of National Statistics supplied death certification
details comprising the immediate cause of death plus the associated
factors.
Laboratory. DNA was extracted from 2 mm3 tissue samples using
DNeasy tissue kit (Qiagen, Crawley, UK). DNA concentration
and quality was measured by spectrophotometry (Nanodrop;
Thermo Fisher Scientific Inc., Wilmington, DE, USA). Bisulphite
treatment of each sample was undertaken using the EZ DNA
Methylation Kit (Zymo Research, Irvine, CA, USA). An aliquot of
the converted DNA (corresponding to 500 ng starting gDNA) was
subjected to microarray analysis (GoldenGate array-Illumina Ltd,
San Diego, CA, USA), (Bibikova and Fan, 2009) examining 1505
CpG sites on 807 genes. Raw methylation data and associated
clinicopathological data have been deposited in ArrayExpress
(accession: E-MTAB-1298).
HPV testing. As some of the tumours overlapped the junction
between oral cavity and oropharynx sites (in particular tonsillar
pillar and soft palate), it was felt appropriate to include HPV status
to clarify the underlying molecular aetiology. Tumour HPV status
was determined using quantitative PCR (qPCR) analysis for
HPV16 DNA presence as previously described (Schache et al,
2011). Briefly, duplicate real-time PCR reactions were conducted
using primers and a FAM-MGB-labelled Taqman probe designed
and optimised to amplify the E6 region of HPV16. Commercially
available primers and a VIC-TAMRA-labelled probe for the
housekeeping gene RNase P were included in the multiplex
reaction to standardise for DNA input. The HPV16-positive
cervical cancer cell line, CaSki (U.K. Health Protection Agency
Culture Collections – 87020501) was used as a positive control and
calibrator. The detection threshold for HPV-positive status was set
at one or more copies of HPV16 E6 gene per diploid genome. A
sample was only considered positive if it met the threshold in both
of the duplicate runs.
Bioinformatics analysis. The array data were initially assessed for
quality. One tumour sample found as an outlier in principal
components analysis (PCA), together with the matching normal
sample were excluded from further analysis. Initial processing of
the data was conducted using the bioconductor package methylumi
(Davis et al., 2012). All 84 CpG sites on the X-chromosome were
excluded from data analysis to avoid gender-specific bias.
R statistical package version 2.14.1 (R, 2012) was employed to
perform Wilcoxon signed-rank and Wilcoxon rank sum tests.
Hierarchical clustering, PCA and survival analysis were performed
using Partek Genomic Suite (Partek Inc., St Loius, MO, USA).
Hypergeometric analysis of pathways enriched by the differential
genes was conducted using MetaCore (GeneGo Inc, Part of
Thomson Reuters, Carlsbad, CA, USA). Genes represented on the
Illumina GoldenGate Cancer Panel I methylation array were used
as reference in the pathway analysis. In statistical analyses, a 5%
FDR cutoff was employed after multiple testing correction of
P-values.
Methylation in tumour/normal paired tissue. When more than
half of the samples (at least 22/43) from a group had average beta
values 40.2, the CpG locus was considered methylated in that
group. The Wilcoxon signed-rank test was employed to identify
statistically significant differential methylation between tumour
and matching normal samples using R statistical package. M-value,
that is, the log2 ratio of intensities of methylated probe versus
unmethylated probe, was employed for Wilcoxon rank sum or
signed-rank tests, as it was recently reported that b values have
severe heteroscedasticity for highly methylated or unmethylated
CpG sites and M-value is a better measure for statistical analyses
(Du et al, 2010). However, as b values provide more intuitive
biological interpretation, differences in methylation levels were
derived using average b values, representing the ratio of methylated
probe intensity and overall intensity, that is, the sum of methylated
and unmethylated probe intensities. An offset of 100 was added to
regularise b when both probe intensities were low. Thus, for each
CpG locus, differential methylation values (D b) were calculated by
subtracting the average b values of tumour samples from the
average b values of the normal samples.
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Comparison was made with previously published HNSCC
methylation data (Poage et al, 2010; Guerrero-Preston et al, 2011)
as well as against a metaanalysis of 63 previous publications
reporting mRNA expression microarray data in HNSCC (Yu et al,
2008). Limiting inclusion criteria to X20 tumour/normal pairs,
this analysis was restricted to four datasets published by Ye
(Ye et al, 2008), Dysvik (Dysvik et al, 2006), Kuriakose (Kuriakose
et al, 2004) and Ibrahim (Ibrahim et al, 2003).
Hierarchical agglomerative clustering of tumour samples was
performed with Euclidean distance measure and average linkage
using average b values of probes selected for differential
methylation between tumour and normal samples. Tumours
identified by this method as having the CpG island methylator
phenotype (CIMP) were validated using Rand Index.
Tumour methylation. Methylation data from tumour samples
were normalised for sequence length and GC content, and
important probes were selected using LumiWCluster package,
thus eliminating arbitrary detection P-value cutoffs in removing
unreliable methylation values (Kuan et al, 2010). Wilcoxon rank
sum test was employed in identifying statistically significant
differences in methylation between samples with and without
extracapsular spread (ECS); human papilloma virus (HPV)-
induced tumour and HPV negative tumours; with and without
lymph node metastasis.
For the generation of a methylation signature associated with
recurrence, univariate Cox regression analysis was performed with
methylation as predictor and freedom from recurrence (FFR) as
response. Freedom from recurrence after resection was calculated
from the date of surgery to the date of recurrence, with censoring
of all other patients. Significant methylation markers associated
with recurrence were selected by filtering on P-value o0.01.
Multivariate Cox regression was also performed with additional
covariates including age, ECS and HPV status. A composite marker
risk score was calculated for each patient from the linear
combination of the methylation values weighted by the Cox
regression coefficient for each selected marker. To quantify the
predictive accuracy of the composite marker, time-dependent ROC
curve at 5th year was generated. Estimation of time-dependent
sensitivity and specificity based on censored outcome was
performed using nearest neighbours algorithm. The area under
the time-dependent ROC curve (AUC) at 5th year was calculated
to quantify the predictive accuracy of the methylation signature. To
assess the uncertainty in the predictive accuracy of the marker,
using 10 000 bootstrap replicates and the bootstrap percentile
method, 95% confidence intervals (CI) of the AUC were calculated.
R packages survivalROC (Heagerty and Saha, 2012) and boot
(Canty, 2002) were employed for the analysis.
RESULTS
Summary of cohort characteristics. The cohort comprised 29
males (66%) and 15 females (34%) with an age range of 29–86
years (median 60 years) at diagnosis. Clinicopathological char-
acteristics of the cohort were similar to our larger OSCC series,
1992–2001 (Table 1), although it is clear that this cohort has higher
pT and pN stage with more involved margins and involved nodes
(Rogers et al, 2009). Although this bias is regrettable, it is
principally related to the inclusion of fewer very small tumours
(14% pT1 here, vs 25% in larger series). This reflects the
understandable reticence and ethical dilemma in sacrificing the
majority of very small tumour for research purposes rather than
for pathological staging. Treatment of tumours was primary
surgery in all cases and post-operative radiotherapy/chemora-
diotherapy was given in 31 (74%) reflecting, again the rather
advanced clinical stages related to the exclusion of the smallest
tumours (Table 1). At the end of study, 19 (43%) of the patients
had died, 11 (25%) of OSCC, 6 (14%) of other causes and 2 (5%)
unknown. Amongst the 25 (57%) survivors, median follow-up data
was 52 months and in all but two cases, the follow-up data was
X43 months. Twelve (27%) cases had histologically proven
recurrence of OSCC.
Promoter methylation analysis in tumour vs normal. Tumour
and matched normal tissues from 43 OSCC patients were analysed
in this study. Unsupervised principal components analysis
identified two clusters along the first principal component
(accounting for 10.7% of variability in the data) that separated
Table 1. Clinicopathological characteristics of the patient samples
employed in the present study compared with our previous study
This study (n¼44) Rogers et al (n¼489)
Gender
Male 29 (66) 302 (62%)
Female 15 (34) 187 (38%)
Tumour differentiation
Poor 3 (7) 49 (10%)
Moderate 27 (66) 286 (60%)
Well 11 (27) 139 (29%)
Deep margins
Clear X5 mm 10 (24)** 237 (48%)
Closeo5 mm 18 (44) 170 (35%)
Involved 13 (32) 82 (17%)
pT
Tis, T1 6 (14)* 134 (27%)
T2 22 (50) 162 (33%)
T3 5 (11) 30 (6%)
T4 11 (25) 163 (33%)
pN
0 19 (43)** 310 (63%)
1 6 (14) 72 (15%)
2þ 19 (43) 107 (22%)
Perineural/perivascular invasion:
Yes 15 (37) 125 (26%)
No 26 (63) 364 (74%)
ECS:
Yes 16 (36) 101 (21%)
No 28 (64) 388 (79%)
Nodal status:
N0 19 (43)* 310 (63%)
NþECS– 9 (20) 78 (16%)
NþECSþ 16 (36) 101 (21%)
Adjuvant radiotherapy
Yes 31 (74)*** 194 (40%)
No 11 (26) 295 (60%)
Recurrence
Yes 12 (29) 120 (25%)
No 29 (71) 369 (75%)
The Statistical Package for the Social Sciences (SPSS, v 18, Chicago) was used to undertake
w2 or Fisher’s exact test. *Po0.05; **Po0.005; ***Po0.0001.
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tumour from normal samples, with a few samples misplaced
(Figure 1). There was a tighter clustering of normal samples
compared with tumour, which may reflect the expected greater
biological heterogeneity in the tumour samples compared with the
paired oral mucosal samples. A number of markers demonstrated
significantly different methylation levels between tumour and
matched normal samples in Wilcoxon signed-rank test. Forty-eight
probes were identified as differentially methylated when a
corrected P-value (FDR) smaller than 0.05 and difference in
average b values (Db) 4þ 0.2 or o 0.2 were used as filtration
criteria. Of these, 32 probes were hypermethylated in tumour
compared with normal tissue, whereas 16 were hypomethylated in
tumour (Supplementary Tables 1 and 2).
Comparison with published HNSCC methylation and mRNA
expression microarray data. A comparison with two previously
published HNSCC methylation array data demonstrated a number
of genes differentially methylated between tumour and normal in
common with our study, all showing concordant methylation
status (Table 2). When the top 25 methylation markers from Poage
et al (2011) were compared with our data, there were 11 common
in the list. A total of 7 out of 10 hypermethylated and 4 out of 15
hypomethyalted in that study were common with our list. In
comparison with Guerrero-Preston et al (2011), 8 genes were
common in the differentially hypermethylated lists. A comparison
of gene promoter methylation with gene expression presented in
the selected microarray datasets (Ibrahim et al, 2003; Kuriakose
et al, 2004; Dysvik et al, 2006; Ye et al, 2008) did not identify any
genes in common with our list demonstrating greater promoter
methylation in tumour. However, 5 differentially hypomethylated
genes were found to be differentially expressed between tumour
and normal in either all or some of the four datasets analysed, with
4 of the hypomethylated genes (SPP1, AIM2, PTHLH and IFNG)
upregulated in tumour (Table 2).
Pathway analysis. Hypergeometric analysis of pathways and
processes altered due to aberrant promoter methylation in tumour
identified the role of VDR in transcriptional regulation of genes
involved in osteoporosis (P¼ 0.03) as a significant canonical
pathway along with glutathione metabolism (P¼ 0.04). On a
process network level, a network representing response to hypoxia
and oxidative stress (P¼ 0.03) was significantly enriched. However,
since the pathway and network analysis was conducted on a
limited set of genes selected, interpretation of the results needs
caution.
HPV status. HPV-associated HNSCC has distinct demographic,
biology and prognosis (Schache et al, 2011; Shaw and Robinson,
2011), and there is growing evidence that the DNA methylation
regulatory pathways are targets for E6 and E7 oncogenes (Burgers
et al, 2007). Accordingly, differences in promoter methylation
between HPV(þ ) and HPV( ) tumours were sought. Genome-
wide methylation differences between these two classes were
previously noted in squamous cell carcinoma cell lines (Sartor et al,
2011). In our study, PCA and unsupervised hierarchical clustering
were capable of distinguishing the two classes based on methyla-
tion data in tumour samples, though to a lesser extent (Figure 2),
although this may be slightly underpowered as only six samples
were HPV-16 DNA positive (13%). However, Wilcoxon rank sum
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Figure 1. Principal components analysis showing the distinction
between tumour and normal samples based on methylation. Average
b values from 43 tumour and matched normal samples were employed
in the analysis. Separation between tumour (hexagon) and normal
(sphere) samples can be visualised in the plot along the first principal
component, with a few misplaced samples.
Table 2. Genes showing differential methylation between tumour and
normal in the present study, which are in common with other


















HOXA9 Hyper Hyper Hyper —
HS3ST2 Hyper Hyper Hyper —
NPY Hyper Hyper Hyper —
HTR1B Hyper Hyper — —
SOX17 Hyper Hyper — —
MME Hyper Hyper — —
EPHA5 Hyper Hyper — —
CALCA Hyper — Hyper —
EYA4 Hyper — Hyper —
HOXA11 Hyper — Hyper —
TAL1 Hyper — Hyper —
WT1 Hyper — Hyper —
EMR3 Hypo Hypo — —
PI3 Hypo Hypo — —
SPP1 Hypo Hypo — High (All)
AIM2 Hypo Hypo — High (Ye)
PTHLH Hypo — — High (Ye,
Kuriakose)
IFNG Hypo — — High
(ibrahim)
CEACAM1 Hypo — — Low (Ye,
Kuriakose)
Methylation status from an Illumina GoldenGate study of 19 HNSCC tumours vs 11
non-malignant samples (Poage et al, 2010) and an Illumina HumanMethylation27 array study
of 4 OSCC tissue versus 4 normal tissue (Guerrero-Preston et al, 2011) are presented.
Comparison with gene expression differences in four HNSCC studies with X20 tumour/
normal pairs (Ye (Ye et al, 2008), Dysvik (Dysvik et al, 2006), Kuriakose (Kuriakose et al, 2004)
and Ibrahim (Ibrahim et al, 2003)) is also presented. Complete list of methylation markers
significantly differential between tumour and normal in our study are presented in
Supplementary Tables 1 and 2.
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test identified nine probes with higher methylation levels in the
HPV(þ ) and five probes with higher methylation levels in
HPV( ) tumours (Po0.05, Db 4|0.2|). Genes methylated at a
higher level in HPV(þ ) were ALOX12, CCNA1, CTSL1, DAPK1,
F2R, FLT1, CADM1, PDX1 and SEZ6L whereas FLJ20712, HIC1,
MT1A, OSM and PDGFB were methylated more in HPV( )
samples. It is of note that CCNA1 and CTSL1 were also identified
in the previous cell line study as highly methylated and with lower
expression in HPV(þ ) compared with HPV( ) (Sartor et al,
2011).
CpG island methylator phenotype (CIMP). CIMP denotes the
concordant tumour-specific DNA methylation observed in
subgroup of tumours, and is associated with distinct clinicopatho-
logical characteristics. When the 48 differentially methylated
promoters in this cohort were clustered based on average b values
using hierarchical agglomerative clustering, two visibly distinct
clusters were identified. One cluster comprising 19 tumour samples
had mostly low b values (median¼ 0.3) and was designated as
‘CIMP-low’. The other cluster with 24 tumour samples had mostly
high b values (median¼ 0.56) and was designated as ‘CIMP-high’
(Figure 3). A PCA plot of average b values from the 48 markers
demonstrated a visible distinction between CIMP-high and CIMP-
low groups of tumour samples along the first principal component
(Supplementary Figure 1). External cluster validation also showed
good agreement between clustering and the CIMP classes (Rand
Index: 0.75). A Kaplan–Meier curve using freedom from
recurrence (FFR) as endpoint demonstrated a statistically non-
significant difference between the CIMP groups (Figure 4), with a
trend towards worse prognosis in patients belonging to the CIMP-
high category (Log-rank P¼ 0.06). This is in contrast to our

































Principal component 1 (34.6%)
6.75.734.763.79–2.03 1.850.88–0.09–1.06–3.0
Figure 2. Principal components analysis showing HPV(þ ) (hexagon)
and HPV( ) (sphere) tumour samples. Average b values from 43
tumour samples were employed in the analysis. One sample with

















































































































































































































































































































































































































Figure 3. Hierarchical clustering heatmap and dendrogram of tumour samples based on methylation markers differential between tumour and
normal tissues. Average b values from the selected 48 probes were used for hierarchical agglomerative clustering using Euclidean distance and
average linkage. CpG island methylator phenotype (CIMP) groups are shown by the two clusters on the dendrogram left of the heatmap, the
bottom cluster designated as ‘CIMP-high’ and the top as ‘CIMP-low’.
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(Shaw et al, 2007). However, CIMP was not an independent factor
determining survival (P¼ 0.3) when a multivariate Cox propor-
tional hazards regression was conducted with other covariates such
as ECS and HPV status.
Methylation signature for extracapsular spread (ECS). Wilcoxon
rank sum test identified 15 probes differentially methylated in
patients with extracapsular spread when compared with patients
without ECS (Po0.05, Delta-beta 4|0.2|); Table 3).Two distinct
clusters were observed in hierarchical clustering of the samples
based on the markers selected (Figure 5), one containing samples
from patients without ECS exclusively and the other a mix of both
ECS and non-ECS samples. Genes differentially methylated
between ECS and non-ECS patient samples included DCC, CALCA
and WT1.
Methylation signature of recurrence. Cox proportional hazards
regression with freedom from recurrence (FFR) identified a 17-
gene signature associated with recurrence (Po0.01; Table 4). A
multivariate Cox regression including covariates age, ECS and
HPV status also found the signature genes to be statistically
significant (Po0.05) except MT1A (0.068) and ATP10A (0.057).
When a risk score generated from linear combination of the
marker values weighted with regression coefficients was assessed
using time-dependent ROC analysis with nearest neighbours
method for censored outcome data, a good concordance of the
risk grouping was observed with recurrence (AUC of time-
dependent ROC at 5th year: 95.7%, 95%CI: 88.07–99.92). With a
P-value cutoff of 0.01, the multivariate Cox regression
analysis identified a 5-gene signature comprising MLLT6_
P957_F, MSH2_P1008_F, NOTCH4_E4_F, PCGF4_P92_R and
TFPI2_E141_F. This signature also was capable and demonstrated
good performance (AUC of time-dependent ROC at 5th year:
92.2%, 95%CI: 81.4–99.3). Out of the five genes, three were the
same as identified from univariate analysis: MLLT6, MSH2 and
NOTCH4. Predictive accuracy of the 3-gene model was also high,
though the uncertainty associated with the prediction was also high
(AUC of time-dependent ROC at 5th year: 92.8%, 95%CI:
80.3–99.3).
DISCUSSION
In this study, we explored the epigenetic landscape of series of oral
squamous cell carcinomas (OSCC) using an array approach.
Significant difference in methylation levels of a number of genes
distinguished tumour tissue samples from their matched normal,
demonstrating epigenetic modifications acquired in the develop-
ment of tumours. It was observed that a number of these
differentially methylated genes in tumours were also identified in
other recent investigations in HNSCC (Poage et al, 2010; Guerrero-
Preston et al, 2011), with three genes in common with both these
studies: HOXA9, HS3ST2 and NPY. In addition, EYA4 and WT1
were also among the list of genes selected for methylation in oral
cancer tissue and pre-operative saliva in a study using similar array
as in the present study (Viet and Schmidt, 2008). It is notable that
all these common genes had consistently concordant methylation
status, even though the studies differed in terms of heterogeneity of
tumours, experimental design or methylation array platform
employed. Methylation of one such gene, HOXA9 that codes for
a homeobox protein, has been suggested as a biomarker for early
detection of OSCC (Guerrero-Preston et al, 2011). In addition to
HNSCC, methylation-associated silencing of the HS3ST2 gene has
been observed in human breast, colon, lung and pancreatic cancers
(Miyamoto et al, 2003) as well as in haematological neoplasms
(Martin-Subero et al, 2009). Interestingly, there was no correlation
between those gene promoter methylation targets and commonly
downregulated genes as noted in the publicly available datasets.
This may be explained by the multiplicity of molecular mechan-
isms regulating gene expression, only one of which is DNA
methylation. Similarly, a metaanalysis of gene expression data from
OSCC samples with matched normal samples, identified common-
ality with our list of 16 genes differentially hypomethylated
between tumour and normal tissues. Among the genes showing
lower levels of methylation and higher levels of expression in
tumour was SPP1, which codes for osteopontin. This secreted
glycoprotein has an important role in determining the oncogenic
Surgery to recurrence (months)



























Log-Rank Chi-sq (df=1) = 3.472569, P-value 0.0623944
Wilcoxon–Gehan Chi-sq (df=1) = 3.560017, P-value 0.0591872
Figure 4. Kaplan–Meier plot of freedom from recurrence (FFR) showing
a trend towards worse prognosis by patients in the CIMP-high group.
FFR in CIMP-high and CIMP-low groups were not significantly different
in log-rank test (P¼ 0.06).
Table 3. Methylation markers differential between patients with and
without extracapsular spread (ECS)
Gene Loci of methylation Strand Db P-value (FDR)
ADCYAP1 P398 F 0.28 0.008
CALCA E174 R 0.33 0.016
CHGA E52 F 0.24 0.025
DBC1 E204 F 0.21 0.021
DCC P471 R 0.34 0.008
DLK1 E227 R 0.34 0.023
HTR1B P222 F 0.31 0.001
KDR P445 R 0.29 0.042
MOS E60 R 0.31 0.005
MT1A P49 R 0.30 0.003
NTRK3 E131 F 0.21 0.039
PENK E26 F 0.21 0.011
SOX17 P287 R 0.29 0.003
WT1 E32 F 0.38 0.010
WT1 P853 F 0.24 0.004
P-values from Wilcoxon rank sum test were corrected for multiple testing (FDR) and
differences in average beta values (Db) between the two groups are presented alongwith
the details of methylation probes. Only differentially hypermethylated probes in patients
with ECS passed the filtration criteria (Db 40.2 and FDRo0.05)
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potential of many cancers and its increased expression is reported
to correlate with tumour progression and metastasis (Senger et al,
1983; Brown et al, 1994; Sodek et al, 2000; Weber, 2001).
The identified putative methylation signatures for ECS and
recurrence in this study require meticulous confirmation in an










































































































































Figure 5. Hierarchical clustering heatmap and dendrogram of tumour samples based on methylation markers differential between patients with
and without extracapsular spread. Average b values from the selected 15 probes were used for hierarchical agglomerative clustering using
Euclidean distance and average linkage.
Table 4. Methylation marker signature of recurrence (FFR) derived from univariate Cox regression
Univariate Multivariate
Probe HR LowCI UpCI P-value HR LowCI UpCI P-value
NOTCH4_E4_F 2.45 1.44 4.17 0.001 2.48 1.28 4.79 0.007
IRAK3_P13_F 1.41 1.15 1.74 0.001 1.31 1.05 1.64 0.016
MLLT6_P957_F 3.56 1.58 8.04 0.002 3.50 1.47 8.34 0.005
MT1A_P600_F 2.04 1.27 3.30 0.003 1.70 0.96 3.00 0.068
CD9_P585_R 3.27 1.45 7.37 0.004 3.14 1.23 8.02 0.017
MSH2_P1008_F 7.66 1.84 31.94 0.005 9.46 1.78 50.38 0.008
ASCL1_E24_F 1.45 1.12 1.89 0.006 1.48 1.05 2.11 0.027
SLIT2_E111_R 1.54 1.13 2.11 0.006 1.64 1.08 2.49 0.020
TBX1_P885_R 1.52 1.13 2.06 0.006 1.40 1.04 1.89 0.026
ESR2_E66_F 1.41 1.10 1.81 0.006 1.29 1.00 1.67 0.046
MYH11_P22_F 1.51 1.12 2.03 0.006 1.43 1.04 1.97 0.029
TNFRSF10C_P7_F 1.72 1.16 2.55 0.007 1.62 1.08 2.43 0.020
POMC_P400_R 1.42 1.10 1.84 0.008 1.38 1.03 1.83 0.029
NES_P239_R 1.75 1.16 2.65 0.008 1.53 1.04 2.23 0.029
GJB2_P791_R 1.71 1.15 2.55 0.008 1.65 1.10 2.47 0.016
ATP10A_P147_F 2.01 1.19 3.39 0.009 1.68 0.98 2.87 0.057
FRZB_E186_R 1.45 1.09 1.91 0.009 1.33 1.02 1.74 0.036
Multivariate Cox regression was also performed with additional co-variates including age, ECS and HPV status. Hazard ratios (HR), lower (LowCI) and upper (UpCI) confidence intervals as well as
P-values for the selected probes from univariate and multivariate Cox regression are displayed. Probes displayed in bold had Po0.01 in multivariate Cox regression as well.
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translation into diagnostic and prognostic biomarkers in tumour
and surrogate tissue. In particular, epigenetic deregulation of
NOTCH signalling in OSCC has been demonstrated as part of a
methylation signature for recurrence. This complements the recent
discovery of common NOTCH1, NOTCH2 and NOTCH3 muta-
tions in HNSCC (Agrawal et al, 2011) using next generation
sequencing. The NOTCH family of genes code for evolutionarily
conserved intercellular signalling pathways which regulating cell–
cell interactions. Further functional exploration of this pathway in
HNSCC and identification of druggable targets are self-evidently a
priority in translation of these findings to the clinic. Genes
differentially methylated between ECS and non-ECS patient
samples included DCC, CALCA and WT1. Interestingly the role
of DCC as an epigenetically regulated tumour suppressor gene in
HNSCC has already been documented in detail (Carvalho et al,
2006; Guerrero-preston et al, 2011). WT1 promoter methylation
has subsequently been proven in our own group to be a clinically
valuable biomarker in lung cancer screening (Nikolaidis et al,
2012) and has also been identified similarly as a biomarker for
cervical cancer (Lai et al, 2008). CALCA promoter methylation has
recently been established as an independent adverse prognostic
factor in leukaemia (Ismail et al, 2011).
Tissue processing with macromolecule extraction was per-
formed on whole biopsy tissue rather than on microdissected tissue
and the composition of both the epithelial and the stromal
compartments was unknown. Epithelial or stromal specific
methylation patterns have been observed previously in both breast
and prostate and so, a more compartment-specific approach may
provide additional insights than a whole-tissue approach
(Rodriguez-Canales et al, 2007; Qiu et al, 2008). The findings in
particular of NOTCH involvement in this mixed cell population of
undefined neoplastic cellularity could have greater significance if
the epithelial component alone was utilised. The relevance of the
epigenome from mixed whole tissue may however be more likely to
reflect in vivo tumour phenotypes as these are reliant upon
epithelial and mesenchymal interactions.
One of the aims of this study was to explore the occurrence of
tumour subgroups with concordant methylation levels at multiple
loci, known as CpG island methylator phenotype (CIMP) (Toyota
et al, 1999). A wide range of genetic and environmental factors
may lead to CIMP, including the increased expression and
abnormal targeting of DNA methyltransferases (DNMTs) (Etoh
et al, 2004; Kim et al, 2006; Teodoridis et al, 2008). We observed
distinct clustering of tumour samples into CIMP-high and CIMP-
low groups with genes differentially methylated between tumour
and normal tissues. We have previously investigated the associa-
tion of CIMP with allelic imbalance, pathology and clinical
behaviour of OSCC (Shaw et al, 2007). In that study, CIMP was
shown to correlate with a marked inflammatory response and less
aggressive tumour biology (Shaw et al, 2007). However, in the
present study, we observed a trend for CIMP-high tumours to be
associated with poor prognosis, though CIMP was not an
independent factor in predicting prognosis. This difference in
observation may stem from the difference in technology and
markers used, as in the previous study we had used only 10 genes
involved in a variety of cellular processes. Although the current
observation of CIMP-high tumours presenting poor survival,
requires external validation with other HNSCC or OSCC series, it
is in line with many other studies in various cancers (Maruyama
et al, 2001; Wei et al, 2002; Brock et al, 2003; Roman-Gomez et al,
2004; Abe et al, 2005).
Although the epigenetic signature associated with HPV-driven
HNSCC has been recently highlighted (Richards et al, 2009; Sartor
et al, 2011), our data offers a somewhat less convincing distinction
in the DNA methylome between HPV(þ ) and HPV( ) cases
than these reports may imply. However, it has to be noted that we
had only very few samples from HPV(þ ) patients. We have
recently documented that many HPV (þ ) cases in our clinical
population are also smokers (Schache et al, 2011), and although
this seems to have little impact on prognostic benefit, this may add
genotoxic stress and blur the lines drawn between smoking-related
and HPV(þ ) cases. Notably, the CCNA1 promoter methylation
seen in HPV(þ ) cases reported by Sartor (Sartor et al, 2011), is
confirmed in our data, whereas epigenetic downregulation of this
gene has been shown to be previously common in OSCC by
pyrosequencing methylation assay (Shaw et al, 2006b, 2008). The
differences in DNA methylome and underlying perturbations of
epigenetic regulatory cellular machinery await further confirma-
tion, elucidation and possible translational application.
We present methylation array data for a significant cohort of
OSCC cases, incorporating detailed pathology and long-term
clinical outcomes in keeping with our previous approach (Rogers
et al, 2009). The benefits of using carefully curated snap-frozen
tissue from paired tumour and normal tissues are self-evident in
undertaking this work. Although comprehensive validation has not
been attempted using single gene methylation assays, the reliability
of this array in similar settings has been previously demonstrated
(Bibikova et al, 2006; Bibikova and Fan, 2009). Additionally,
comparison with expression array datasets (Yu et al, 2008) and the
limited methylation array data available in OSCC (Viet and
Schmidt, 2008; Poage et al, 2010; Guerrero-Preston et al, 2011) has
been carried out, with confirmation of a number of targets.
Although the spectrum of OSCC presented here is skewed towards
larger tumours where tissue procurement is safely achieved, in
other respects, this cohort represents a consecutive series treated
uniformly according to written and audited protocols. The tissue
procurement is associated with an academic tertiary centre
responsible for treatment of all OSCC cases from a discrete
geographical population of 2.5 million.
It is evident that epigenetic regulation features as a major
mechanism in the carcinogenesis of OSCC and that several
pathways appear to be specifically epigenetically deregulated in the
cases showing greatest biological aggression that often prove
refractory to aggressive conventional therapies. The potential to
target epigenetics with novel agents seems a rational approach.
Additionally, the translational capacity of epigenetic biomarker
panels may be clinically applicable in screening, diagnosis,
prediction of response and prognostication.
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